16 hrs ago
The Motley Fool
Eli Lilly Struggles for Pipeline Success
The company announced it was ditching development of edivoxetine as a new treatment for depression after three separate phase 3 studies failed to show significant improvements over a selective serotonin reuptake inhibitor alone, the current first-line therapy for depression.
Mon Dec 09, 2013
Schizophrenia Usually Strikes First in Young Adults
Unlike virtually every other mental illness, schizophrenia is fairly unique in that its first onset is nearly always in young adulthood - not childhood or as a teen, and rarely after one's 30s.
Alkermes plc Presents Data On Two Late-Stage Clinical Candidates,...
Alkermes plc Presents Data On Two Late-Stage Clinical Candidates, Aripiprazole Lauroxil And ALKS 5461, At 52nd Annual ACNP Meeting Alkermes plc today announced that data will be presented at the 52nd Annual Meeting of the American College of Neuropsychopharmacology in Hollywood, Fla., Dec. 8-12, 2013, related to the company's two most advanced ... (more)
Sat Dec 07, 2013
N-acetylcysteine as an adjunct to risperidone for treatment of...
Despite the burden of negative symptoms on quality of life in schizophrenic patients, no completely effective treatment has been developed to address such symptoms yet.
Fri Dec 06, 2013
Amanda Bynes advised against fashion school
Amanda Bynes has been advised against enrolling at the Fashion Institute of Design and Merchandising , in California so soon after being released from psychiatric treatment.
Thu Dec 05, 2013
Judge 'irritated' as Amanda Bynes fails to appear in court over marijuana bong-throwing incident
Already in trouble? Amanda Bynes failed to show up for a mandatory hearing at a New York court on Thursday, leaving the judge on the bong-tossing case 'visibly annoyed' The 27-year-old failed to show up for a mandatory hearing at a New York court on Thursday, leaving the judge on the bong-tossing case 'irritated,' reports the NY Daily News .
Amanda Bynes 'secretly discharged from rehab'
Washington, Dec 5: Amanda Bynes, who was undergoing treatment for schizophrenia and bi-polar disorder in a rehab center in Malibu, California, has been secretly discharged, according to reports.
Wed Dec 04, 2013
Can we trust the internet to measure psychotic symptoms?
Online studies are increasingly utilized in applied research. However, lack of external diagnostic verification in many of these investigations is seen as a threat to the reliability of the data.
The Motley Fool
AstraZeneca Eyes Forest Labs as Shares Rise
Long rumored to have eyed Forest Laboratories as a potential acquistion, AstraZeneca allegedly gained board approval for a $15 billion cash offer, secured advisors and started talks with Forest.
Mon Dec 02, 2013
UPDATE 1-Forest Labs to buy schizophrenia drug, cut costs
Forest Laboratories Inc, which is facing patent expirations on several of its biggest drugs, on Monday said it plans to buy rights to a new schizophrenia treatment from Merck & Co and cut annual operating costs by $500 million in fiscal 2016.
The Modesto Bee
Forest Labs plans to cut $500M in spending
The drugmaker also acquired the U.S. marketing rights to Saphris, a Merck & Co. drug used to treat schizophrenia and bipolar mania.
Janssen: Xeplion Effective in Patients with Schizophrenia
Janssen Pharmaceutica NV has announced results of the PALMFlexS study during The German Society for Psychiatry and Psychotherapy, Psychosomatic Medicine and Neurology congress in Berlin, 27-30 November 2013.1-8 Data showed flexible maintenance dosing* with XeplionA was associated with a clinically relevant treatment response, and was well tolerated ... (more)
Schizophrenia Global Clinical Trials Review, H2, 2013 - New Market Study Published
GlobalData's clinical trial report, "Schizophrenia Global Clinical Trials Review, H2, 2013" provides data on the Schizophrenia clinical trial scenario.
Sun Dec 01, 2013
EpiCast Report: Schizophrenia - Epidemiology Forecast to 2022 - New Report Available
Schizophrenia is a chronic, severe, and disabling group of psychotic disorders characterized by fundamental disturbances of thinking such as hallucinations, delusions, disorganized communication, and reduced motivation.
Fri Nov 29, 2013
New Data Show Efficacy, Safety and Tolerability of XeplionA in...
FOR MEDICAL TRADE MEDIA ONLY Janssen Pharmaceutica NV has announced results of the PALMFlexS study during The German Society for Psychiatry and Psychotherapy, Psychosomatic Medicine and Neurology congress in Berlin, 27-30 November 2013.
Wed Nov 27, 2013
Fairfield meeting to discuss challenges of treating schizophrenia
The Fairfield chapter of the National Alliance on Mental Illness is presenting a talk on what is being done to help those with treatment-resistant schizophrenia and schizoaffective disorder.
Tue Nov 26, 2013
Adjuvant therapy with minocycline for schizophrenia (The MINOS...
Schizophrenia is understood to be a heterogeneous brain condition with overlapping symptom dimensions.
Mon Nov 25, 2013
Research slows on mental health drugs as investment shrinks
Research into medications to treat mental health disorders, which affect almost a quarter of the US population, has slowed as major pharmaceutical companies cut back investment in this area, psychiatrists say.
Sat Nov 23, 2013
FDA Rejects Schizophrenia Drug Cariprazine
The FDA has rejected a new drug application for cariprazine , an atypical antipsychotic for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
Poor Social Functioning in Childhood Linked to Greater Schizophrenia Risk
Researchers found that poor social functioning as rated by teachers on a psychometric scale, significantly set apart children who later developed schizophrenia-spectrum disorder from those who did not develop mental illness and also those who developed other mental health disorders.